Top Ten articles in the Pharma Industry this week

pharmafile | November 11, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |  November, news, pharmaceutical, top 10, top ten, top ten stories 

This week has seen pharmaceutical companies defending their patent protections and host of new collaboration spring up between companies. Read here to catch up on this and the other biggest news stories that have been viewed on our website.

10. Cancer Research UK enters new oncology partnership

The firm and its commercial arm haven entered into an agreement with TYG Oncology to develop a new vaccine for advanced cancers.

9. Coherus knocked back by AbbVie’s Humira patent protection

Coherus Biosciences, a developer of biosimilars, has suffered a blow in their petition for Inter Partes Review of one of AbbVie’s key formulation patents for Humira.

8. FDA clears digital sensor for GSK inhaler

Propeller Health’s digital sensor receives 510(k) clearance for use with GSK’s Ellipta dry powder inhaler.

7. NICE turns down Amgen’s multiple myeloma drug

Kyprolis (carfilzomib) is rejected by NICE for its routine use in the treatment of multiple myeloma in combination with Celgene’s Revlimid (lenalidomide) and dexamethasone or dexamethasone.

6. Pfizer’s breast cancer drug gets EU approval

The European Union has approved Ibrance following a positive recommendation from the European Medicines Agency (EMA) in September.

5. BenevolentAI announces licensing agreement with Janssen

BenevolentAI, a British artificial intelligence company, announced a licensing agreement to develop a select number of drug candidates with Janssen, of Johnson & Johnson.

4. Collaboration on new therapeutic vaccine for HIV shows promise

Janssen, part of Johnson & Johnson, released details on 9 November of the results of a new study looking into a new approach to combatting human immunodeficiency virus (HIV-1)..

3. FDA approves first therapy for paediatric psoriasis treatment

Amgen’s Enbrel has been given approval by the FDA for expanded use to treat children with chronic moderate-to-severe plaque psoriasis. This is the first such approval for the systemic therapy to treat paediatric patients from ages 4 to 17.

2. Pfizer to shut two out of three manufacturing plants in UK

Pfizer has announced that it will close two of the three manufacturing plants it still holds in the UK. The decision places at risk 370 jobs.

1. GSK launches patent infringement action against Pfizer

GSK attempts to protect its market share with allegations that Pfizer’s Trumenba copies its popular meningococcal group B vaccine Bexsero.